Joint project with
. This link opens in a new tab.
What is CAR-T therapy?
Reading time: 2 min
CAR-T (Chimeric Antigen Receptor T-Cell) therapy consists of the use of the patient's own T lymphocytes. A species similar to an antibody is added to these cells via genetic modification that recognises the antigen tumour (a substance called a scFv fragment) and one of the membrane receptors of the T lymphocytes. This is why it is called a "chimeric" receptor.
How is it performed?
The first step in CAR-T therapy is apheresis on the patient. The blood sample collected is inserted into a device called a cellular bioreactor, which separates the T-cells from the rest of the blood cells. After separation, these cells are genetically modified to give them their anti-tumour capacity.
Once modified, the CAR T-cells are reproduced within the bioreactor until the number of cells necessary for the desired effectiveness is obtained. These CAR T-cells are then infused back into the patient to attack the malignant cells.
All patients treated with CAR-T therapy are followed up and monitored. A laboratory analysis is performed to determine parameters such as the CAR T-cell population in the blood; the presence of different antibodies; and levels of some types of immune cells.
This patient follow-up allows specialists to assess the effectiveness of the treatment and make the most appropriate decisions in each situation.
The CAR-T therapy production process must be according to specific “Good Manufacturing Practice” (GMP) standards.
GMP comprises a set of measures to ensure the quality of medicines and protect the patient and manufacturer. For example, there are a set of specifications to ensure the treatment is of a proper composition; its production is homogeneous; its format and dosage are appropriate; and there is no contamination.
Joint project with
. This link opens in a new tab.
Sorry this content wasn't helpful to you. Send us your comment and we will take it into account to continue improving.
Thanks for your help!
An error has occurred and we were unable to send your opinion, please try again later.
Substantiated information by:
Mariona Pascal Capdevila
Sergio Navarro Velázquez
Published: 21 September 2023
Updated: 21 September 2023
Subscribe
Receive the latest updates related to this content.
Thank you for subscribing!
If this is the first time you subscribe you will receive a confirmation email, check your inbox
An error occurred and we were unable to send your data, please try again later.
